Article
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Defining On-Treatment Remission in Plaque Psoriasis
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
Low BSA in Psoriasis May Still Mean High Disease Burden
Patients With GPP Face Elevated Mortality Risk, Study Finds
Biosimilar Starjemza Gains FDA Approval as Ustekinumab Shows Significant Psoriasis-Itch Relief
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis